Literature DB >> 18096765

Cytotoxic T lymphocytes overcome Bcl-2 inhibition: target cells contribute to their own demise.

Ing Swie Goping1, Tracy Sawchuk, Aja Rieger, Irene Shostak, R Chris Bleackley.   

Abstract

Cytotoxic T lymphocytes (CTLs) eliminate pathogenic cells in large part through the activity of the serine protease granzyme B (grB). However, while the apoptotic activity of grB is blocked by over-expression of Bcl-2, CTLs can still kill target cells through an ill-defined Bcl-2-independent pathway. In this report, we have identified key modulators of this Bcl-2-independent cell-death pathway, which is induced by CTLs and not purified components. Surprisingly, activation of this pathway is reliant on grB. Furthermore, this novel pathway requires mitochondrial contribution through triggering of permeability transition and generation of reactive oxygen species, yet is functional in the absence of Bax/Bak. This pathway stimulates movement of target cell mitochondria toward the point of contact with the CTLs and importantly, inhibition of this directed movement attenuates killing. Therefore, we propose that CTLs initiate a target cell response that activates multiple mitochondrial pathways. This ensures that CTLs can eliminate those target cells that have compromised apoptotic potential due to overexpression of Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096765     DOI: 10.1182/blood-2007-08-105221

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Deregulation of mitochondrial membrane potential by mitochondrial insertion of granzyme B and direct Hax-1 cleavage.

Authors:  Jie Han; Leslie A Goldstein; Wen Hou; Christopher J Froelich; Simon C Watkins; Hannah Rabinowich
Journal:  J Biol Chem       Date:  2010-04-13       Impact factor: 5.157

2.  Toxoplasma gondii inhibits granzyme B-mediated apoptosis by the inhibition of granzyme B function in host cells.

Authors:  Tatsuya Yamada; Tadakimi Tomita; Louis M Weiss; Amos Orlofsky
Journal:  Int J Parasitol       Date:  2011-02-15       Impact factor: 3.981

3.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.

Authors:  Liang Shan; Kai Deng; Neeta S Shroff; Christine M Durand; S Alireza Rabi; Hung-Chih Yang; Hao Zhang; Joseph B Margolick; Joel N Blankson; Robert F Siliciano
Journal:  Immunity       Date:  2012-03-08       Impact factor: 31.745

4.  Granzyme B inhibits vaccinia virus production through proteolytic cleavage of eukaryotic initiation factor 4 gamma 3.

Authors:  Marcelo Marcet-Palacios; Brenda Lee Duggan; Irene Shostak; Michele Barry; Tracy Geskes; John A Wilkins; Akiko Yanagiya; Nahum Sonenberg; R Chris Bleackley
Journal:  PLoS Pathog       Date:  2011-12-15       Impact factor: 6.823

Review 5.  Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions.

Authors:  Shih-Chi Su; Wen-Hung Chung
Journal:  Toxins (Basel)       Date:  2014-01-03       Impact factor: 4.546

6.  CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.

Authors:  Gerritje J W van der Windt; Arnon P Kater; Anne W J Martens; Susanne R Janssen; Ingrid A M Derks; Homer C Adams Iii; Liat Izhak; Roel van Kampen; Sanne H Tonino; Eric Eldering
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 7.  Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity.

Authors:  Karoliina Tuomela; Ashley R Ambrose; Daniel M Davis
Journal:  Front Immunol       Date:  2022-03-23       Impact factor: 7.561

8.  Apoptosis Induction by the Total Flavonoids from Arachniodes exilis in HepG2 Cells through Reactive Oxygen Species-Mediated Mitochondrial Dysfunction Involving MAPK Activation.

Authors:  Huimin Li; Jing Chen; Chaomei Xiong; Han Wei; Changchang Yin; Jinlan Ruan
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-28       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.